drugset / Trial / NCT00567255

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

NCT00567255

Phase 3 Completed 1496 enrolled Orexigen Therapeutics, Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity.

Timeline

Start
2007-12
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 360 mg
Subject Naltrexone Small molecule 32 mg

Indications